CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder saving therapeutics for patients with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life.
Cretostimogene grenadenorepvec
is a targeted oncolytic immunotherapy agent that has shown remarkable efficacy in bladder cancer.
CG Oncology by the Numbers
Active clinical programs
with planned studies soon underway. See current clinical trials.
%
Complete response rate
at any time for cretostimogene in combination with KEYTRUDA®
%
Complete response rate
at 12 months for cretostimogene in combination with KEYTRUDA®
Latest News
CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations
Company appoints Ambaw Bellete as President and Chief Operating Officer, Swapnil Bhargava, Ph.D. as Chief Technical Officer, and Vijay Kasturi, M.D. as Chief Medical Officer With decades of proven experience, they bring leadership to successfully lead...
CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Support Continued Advancement of Clinical-Stage Bladder Cancer Pipeline
- Co-led by new investors Foresite Capital and TCGX - - Proceeds to advance late-stage clinical programs in bladder cancer towards FDA approval - August 2, 2023, 8:00 AM Eastern Standard Time IRVINE, Calif. (BUSINESSWIRE)--CG Oncology, Inc. today announced the close...
CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with Cretostimogene Grenadenorepvec in BCG-Unresponsive High-Risk NMIBC
IRVINE, Calif.--(BUSINESS WIRE)-- CG Oncology, Inc., announced today completion of patient enrollment for BOND-003, a single arm, Phase 3, monotherapy study evaluating cretostimogene grenadenorepvec in patients with high-risk non-muscle invasive bladder cancer (NMIBC)...
